| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = -$350,000 ) |
| | 2022 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 000 | 1 | FDA | 7/7/2022 | -$75,000 |
| | 2022 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005065 | 3-Month Toxicity and Toxicokinetics Intravenous Infusion Study in Beagle Dogs Giv | 000 | 1 | FDA | 7/7/2022 | -$125,000 |
| | 2022 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 000 | 1 | FDA | 7/7/2022 | -$75,000 |
| | 2022 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005069 | RC-2Beta In Vitro Growth Inhibition Study in support of the Canine Lymphoma and C | 000 | 1 | FDA | 7/7/2022 | -$75,000 |
|
| Issue Date FY: 2020 ( Subtotal = -$75,000 ) |
| | 2020 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 000 | 1 | FDA | 8/7/2020 | -$75,000 |
|
| Issue Date FY: 2019 ( Subtotal = -$150,000 ) |
| | 2019 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 000 | 1 | FDA | 3/26/2019 | -$75,000 |
| | 2019 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 000 | 1 | FDA | 3/26/2019 | -$75,000 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005065 | 3-Month Toxicity and Toxicokinetics Intravenous Infusion Study in Beagle Dogs Giv | 000 | 1 | FDA | 9/20/2017 | $0 |
| | 2017 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 000 | 1 | FDA | 2/23/2017 | $0 |
| | 2017 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005069 | RC-2Beta In Vitro Growth Inhibition Study in support of the Canine Lymphoma and C | 000 | 1 | FDA | 9/20/2017 | $0 |
| | 2017 | 2014 | OGENX THERAPEUTICS CORPORATION | 1290 GULF BLVD STE 1201 | CLEARWATER | FL | 33767-2740 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 000 | 1 | FDA | 4/11/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $0 ) |
| | 2016 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005069 | RC-2Beta In Vitro Growth Inhibition Study in support of the Canine Lymphoma and C | 001 | 1 | FDA | 7/20/2016 | $0 |
| | 2016 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005065 | 3-Month Toxicity and Toxicokinetics Intravenous Infusion Study in Beagle Dogs Giv | 000 | 1 | FDA | 5/12/2016 | $0 |
| | 2016 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 000 | 1 | FDA | 2/5/2016 | $0 |
| | 2016 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 001 | 1 | FDA | 7/20/2016 | $0 |
| | 2016 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 001 | 1 | FDA | 4/14/2016 | $0 |
| | 2016 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005069 | RC-2Beta In Vitro Growth Inhibition Study in support of the Canine Lymphoma and C | 000 | 1 | FDA | 5/12/2016 | $0 |
| | 2016 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005065 | 3-Month Toxicity and Toxicokinetics Intravenous Infusion Study in Beagle Dogs Giv | 001 | 1 | FDA | 7/20/2016 | $0 |
| | 2016 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 000 | 1 | FDA | 2/5/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $0 ) |
| | 2015 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 000 | 1 | FDA | 3/25/2015 | $0 |
| | 2015 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005065 | 3-Month Toxicity and Toxicokinetics Intravenous Infusion Study in Beagle Dogs Giv | 000 | 1 | FDA | 4/6/2015 | $0 |
| | 2015 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 000 | 1 | FDA | 3/25/2015 | $0 |
| | 2015 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005069 | RC-2Beta In Vitro Growth Inhibition Study in support of the Canine Lymphoma and C | 000 | 1 | FDA | 4/6/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $350,000 ) |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 002 | 1 | FDA | 5/22/2014 | $0 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005069 | RC-2Beta In Vitro Growth Inhibition Study in support of the Canine Lymphoma and C | 001 | 1 | FDA | 7/14/2014 | $0 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005065 | 3-Month Toxicity and Toxicokinetics Intravenous Infusion Study in Beagle Dogs Giv | 000 | 1 | FDA | 7/1/2014 | $125,000 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 000 | 1 | FDA | 1/30/2014 | $75,000 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 002 | 1 | FDA | 5/22/2014 | $0 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005039 | A Pilot/Supportive Study of RC-2Beta to be Used in the Treatment of Canine Lympho | 001 | 1 | FDA | 5/20/2014 | $0 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005069 | RC-2Beta In Vitro Growth Inhibition Study in support of the Canine Lymphoma and C | 000 | 1 | FDA | 7/1/2014 | $75,000 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005065 | 3-Month Toxicity and Toxicokinetics Intravenous Infusion Study in Beagle Dogs Giv | 001 | 1 | FDA | 7/11/2014 | $0 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 000 | 1 | FDA | 1/30/2014 | $75,000 |
| | 2014 | 2014 | Ogenx Therapeutics Corporation | 1290 Gulf Blvd. | CLEARWATER | FL | 33767 | PINELLAS | USA | R01FD005040 | A Pilot/ Supportive Study of RC-2Beta to be Used for the Treatment of Non-Resecta | 001 | 1 | FDA | 5/20/2014 | $0 |
|
|
